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ABSTRACT 
 
The Center for Disease Control approximates that one out of every four women carries 
Group B Streptococcus (GBS) bacteria. GBS can be passed to the neonate from the 
pregnant mother during vaginal delivery or in utero by the ascending route1. Some 
notable diseases that are caused by GBS are sepsis, meningitis, pneumonia, certain skin 
infections, and types of bone and joint infections2. One of the most important virulence 
factors for GBS is capsule, which has sialic acid residues attached to the polysaccharide 
chains helping to prevent the host immune system from being triggered when the 
pathogen is present. CpsA is a protein found in Streptococcus agalactiae, GBS, that plays 
a role in production and ligation of the capsule to the cell wall. This research aims to 
understand the mechanisms used by the CpsA protein to create and attach the capsule. 
Previous research in this lab has specifically focused on the two aspartic acid residues in 
the metal binding site of CpsA. This research showed that changing negatively charged 
aspartic acid residues to a different neutral amino acid resulted in decreased capsule 
expression. To continue the experiment, this project will be focusing on the third residue 
within this metal binding domain, arginine, and mutating it to an alanine. Some 
hypothesized results include that the mutation will cause less capsule production or 
attachment, increased resistance in zebrafish, and a possible difference between the single 
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Group B Streptococcus 
The Center for Disease Control approximates that one out of every four women 
carries Group B Streptococcus (GBS) bacteria. For an opportunistic pathogen, this 
bacteria can inhabit the vaginal tract and other areas on the body without causing any 
harm for the host with a healthy immune system. However, this bacteria has a 55% 
mortality rate in infected newborns3 as well as high mortality rates in the elderly and 
other immunocompromised people. GBS can be passed to the neonate from the pregnant 
mother during vaginal delivery or in utero by the ascending route1. Intrapartum antibiotic 
prophylaxis is currently the only way to aid in prevention of transferring of GBS bacteria 
from mother to neonate. However, there are a number of complications that are 
associated with the procedure, including increased resistance to antibiotics as well as 
possible negative long term effects on the neonate as well as possible effects on the 
mother’s gut microbiota4.  
Neonates experience both early onset and late onset disease types. Early onset 
disease occurs within the first week of a baby’s life, whereas late onset is categorization 
by the disease occurring after the first week until the end of the first three months of 
life2,5,6. Both early and late onset cause similar infections such as sepsis, bacteremia, 
pneumonia, and meningitis, with meningitis being more commonly associated with late 
onset GBS.  
Immunocompromised adults, as well as, the elderly are also specific populations 
that are at risk for GBS disease, though are at a lower risk than newborns4. Many of the 
diseases that occur in affected neonates are the same as diseases that occur in adults, such 
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as sepsis, meningitis, pneumonia, certain skin infections, and types of bone and joint 
infections1. If the mechanisms of pathogen infection can be better understood, more 
targeted drug therapies can be created to more effectively prevent these diseases, 
including the development of a specific vaccination.  
Group B Streptococcus is a Gram positive bacterium, which means that this 
bacteria has a thicker outer cell layer compared to Gram negative bacteria. In GBS 
specifically, there is a capsule around the cell, exterior to the thick outer cell wall7. This 
capsule helps to prevent the immune system of the host from being triggered when the 
pathogen is present8. The capsule also specifically allows for the bacteria to survive in the 
bloodstream. Usually the immune system is activated early by any unknown pathogen 
and the macrophages and neutrophils can phagocytose the bacteria. However, the capsule 
inhibits phagocytosis by the immune cells. The mechanism for this inhibition is the 
production of sialic acid molecules on the capsule that are the same as those found on our 
cells9,10. Therefore, this bacteria looks like self and is not recognized by the host immune 
system. Without the immune system being triggered, the bacteria can grow, multiply, and 
colonize the host without intervention.  
CpsA is a protein found in GBS that that plays a role in production and ligation of 
the capsule to the outer cell wall8. Knowledge gained about the functions of the CpsA 
protein is key for understanding the mechanisms used to create and attach the capsule to 
the cell wall. Using this information may allow new therapeutic strategies that could 
target the CpsA protein and cause the bacteria to be less virulent. If the bacteria was less 
virulent, the immune system would be able to better detect and kill the invading 
pathogen. This would potentially enable physicians to prescribe a medication that is not 
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an antibiotic and help prevent development of antibiotic resistance that is becoming an 
increasing issue.  
CpsA Structure 
 CpsA is a membrane protein, with three transmembrane regions, and two 
extracellular domains, the accessory domain and the LytR domain (Figure 1).  
Figure 1 
The role of CpsA has been determined as an activator of transcription and capsule 
production9,11. Not only is the CpsA protein highly conserved in different GBS strains but 
is also found in Streptococcus pneumoniae and Streptococcus iniae. There is 
approximately 70% conservation between GBS and S. pneumoniae (Figure 2).	
Figure 2 
 This protein is closely associated with capsule production as results have shown that 
when the protein is deleted, a significant reduction in capsule was present9,12. This non-
polar deletion did not affect any proteins downstream from the deletion site. However, 
CpsA has been shown to be multifunctional as it has a role in cell wall integrity, DNA 
binding, inhibition of complement, and enzymatic roles as well as its role with capsule 
activation9,11.  
Figure 2. Amino Acid Sequence of GBS and S. pneumoniae. The top sequence is GBS and the bottom is S. 
pneumoniae. The highlighted letter is the amino acid that was mutated in this research. The asterisks indicate the same 
amino acid, the colon indicated similar amino acids.  




Previous work demonstrated that CpsA can regulate and activate transcription13. 
This protein is closely associated with capsule production as results have shown that 
when the protein is deleted, a significant reduction in capsule was present8,11. This non-
polar deletion did not affect any proteins downstream from the deletion site. However, 
CpsA has been shown to be multifunctional as it has a role in cell wall integrity, DNA 
binding, inhibition of complement, and enzymatic roles among its role with capsule12. 
While still being studied, there is a lot about this protein that is not known, specifically 
the mechanism of how it regulates capsule production.   
Kawai et al performed various studies on this protein in S. pneumoniae in 201111. 
The main goal of this study was to identify regions on the Cps2A protein that were 
significant in function. Cps2A is the analogous protein to GBS CpsA that is found in S. 
pneumoniae. The two major extracellular domains found within the protein are the 
accessory domain and the Lyt-R domain. These domains fold completely independently, 
therefore indicating separate functions11. There is a peptide loop that connects the two 
domains together, however this area was unable to be assigned a structure. The 
movement and variability in this region prevented a particular folding pattern from being 
identified. Kawai et al’s research showed what specific connections were seen to be 
important in the Lyt-R region. The crystal structure of this domain was found to have a 
buried lipid molecule, leading them to suggest that it may be acting as the ligase that 
enzymatically ligates the capsule to the cell wall. The capsule structure starts as 
monosaccharides on the intracellular leaflet of the membrane. Then, the enzyme flippase 
allows the capsule to be flipped extracellularly, where polymerases add polysaccharides 
	5 
to grow chain and finally a ligase enzyme attaches the capsule to the peptidoglycan 
layer6,7. 
The Kawai et al study solved the crystal structure of the protein and was able to 
use that data to then identify certain amino acid residues that could be most prominent in 
capsule production and attachment. One such area located was a magnesium metal 
binding site (Figure 3). 	This site is an 
area of three amino acids, two aspartic 
acid (D234, D246) and one arginine 
(R267), that bind to a magnesium metal 
ion and activates an enzyme catalysis 
site. However, GBS is used for this 
research project and the analogous 
residues are in slightly different 
positions. The three key residues for metal binding in GBS are D238, D250, and R278.   
 Previous research in the Neely lab has specifically focused on the two aspartic 
acid residues in the metal binding pocket14. This research showed that changing negative 
aspartic acid residues to a different neutral amino acid resulted in decreased capsule on 
the cell. To continue the 
analysis, this project focused 
on the third residue, arginine 
(R) and mutated it to be an 
Figure 3. Metal Binding Structure of S. agalactiae. 
R267A is shown with blue carbons.	
Figure 4. Amino Acid Sequence of Group B Strep. Wild Type sequence 




alanine (A). The mutation was created independently from the previous mutations of the 
aspartic acids. Arginine is a positively charged amino acid and alanine is neutral. The 
location in GBS of the arginine that was mutated is R271 (Figure 4). 
Research Goals 
 The main goal of this experiment is to have a more mechanistic understanding of 
the CpsA protein. This was accomplished by creating create a point mutation to 
determine how GBS is affected by the mutation and analyze the effects of the constructed 
mutant strain on virulence. The hope is that this information could aid researchers in 
synthesizing new medications that decrease bacterial virulence by promoting the immune 
system’s normal functions. 
 The zebrafish infectious disease model was used as these fish have similar 
immune systems to humans. During their early stages of development, zebrafish only 
have innate immunity, which is when injections of GBS strains for this research will be 
done. Sine the infections to zebrafish larvae are acute infections, only innate immunity 
plays a role. The experiment will look at acute infections, which entails determining 
zebrafish survival over three days without adaptive immunity playing a role. Zebrafish 
are still transparent at the larva stage of development and can be easily observed 
internally under a microscope. Infections will be injected into the yolk sac. This type of 
injection is similar to intraperitoneal characteristics of humans as well as being an easier 
target for injection.  
Some hypothesized results are the mutation will cause less capsule production or 
attachment, an increase in chain length, and decreased virulence in zebrafish. Since the 
original arginine is a positively charged molecule, the same change as the magnesium ion 
that fits in this binding pocket, there might not be as great of a phenotypic change with 
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mutating the residue to alanine, a neutral molecule. The previous findings showed that 
mutating the two aspartic acids resulted in increased chain length and decreased capsule. 
The arginine in this pocket is proposed to help coordinate the two aspartic acid residues 
in the correct conformation to hold the magnesium ion11.These findings are consistent 




Mutant Strain Construction 
The plasmid pLZ12-rofA-pro (strain # 12E34) was digested with PstI and BamHI. 
Polymerase Chain Reaction was performed using GBS, strain 515 chromosome as 
template. The primers used for the first reaction were 5’ GBS-CpsA-RBS-BamHI and 3’ 
CpsA-R271A. This reaction created an 810 base pair fragment with the R271A single 
mutation. The primers used for the second reaction were 5’ CpsA-R271A and 3’GBS-
CpsA-full-PstI. This reaction created a 650 base pair fragment, also including the 
mutation. The fragments were then gel isolated to purify the fragments away from the 
chromosomal DNA and to confirm sizes. The splice overlap extension reaction (PCR-
SOE) was used to combine both fragments with the mutation using primers 5’ GBS-
CpsA-RBS-BamHI and 3’GBS-CpsA-full-PstI (Figure 5). This created a full size 
fragment of 1470 base pairs containing the mutation. The whole fragment was gel 
purified and the correct size was confirmed. The fragment was then digested with BamHI 
and PstI. The digested fragment was then ligated into the digested vector, followed by 
transformation into competent E. coli by electroporation. Plasmid DNA was isolated 
from transformants and sequenced to confirm the mutation was in the correct position 
and that there were no other mutations in the rest of the cpsA gene. Plasmids showing the 
correct sequence were then transformed into the WT GBS strain and the ΔcpsA GBS 
strain. 
Figure 5	 
Figure 4. PCR SOEing Reaction. The single amino acid mutation was made 
through a combination of three reactions.	
	9 
Enzyme-linked immunosorbent assay (ELISA) 
The ELISA was used to quantitatively determine the amount of capsule present on the 
cell surface of each strain. Overnight cultures were grown in 10 mL of Todd-Hewitt 
Yeast Broth (THY-B) and 3ug/ml chloramphenicol. The secondary antibody was 
preabsorbed with 2.5 mL of a mixture of the WT and ΔCpsA cultures for 1 hour and filter 
sterilized. The overnight cultures were normalized to an OD600 of 0.75 and incubated 
with a 1:20,000 dilution of primary antibody (rabbit anti-serotype 1a) for 1 hour at 4˚C. 
After 3 washes in Tris-buffered saline + 0.1% Tween (TBST), the cultures were 
incubated with secondary antibody (Goat anti-rabbit IgG conjugated to alkaline 
phosphatase) for 1 hour at 4˚C. Negative controls were the WT and ΔCpsA strains that 
were only incubated with the secondary antibody and not the primary. After 3 final 
washes in TBST, a liquid alkaline phosphatase assay was performed on all reactions in 
triplicate at no dilution, 1:2, and 1:4. The results were read at OD405 and OD600.   
 
Cell Morphology 
Overnight cultures were grown in 5 mL of THY-B and 3ug/ml of chloramphenicol. Six 
microliters of each strain were placed on a slide and observed under the compound 
microscope at 1000X. Ten fields of view were photographed for each strain. Chain length 
was counted and analyzed for mean and mode and compared to other groups. 
 
Virulence Assays 
To determine survival of zebrafish larvae infected with each strain, virulence assays were 
performed. Two day old dechorionated zebrafish larvae were used for virulence assays. 
Overnight cultures were grown in 5 mL of THY-B and 3ug/ml chloramphenicol, 
subcultured the next morning and grown to 1x108 CFU/mL. Yolk sac injection were 
performed with all strains at a dose if 100 CFU.  Inoculum was confirmed by plating on 
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agar plates. After all injections completed, the fish incubated at 27-29°C and monitored 





 Observation of the Wild Type GBS strain with an empty plasmid indicates that 
the average number of cocci per chain (i.e. chain length) is between one and two cocci 
(Figure 6). When compared to the ΔCpsA strain with empty plasmid, the Wild Type 
strain with empty plasmid exhibits much lower average chain length (Figure 6, columns 
1,3). This is further seen when comparing the frequency of cocci per chain between the 
two strains (Figures 7 and 8). The Wild Type strain with empty plasmid has the highest 
frequency of chain lengths between one and three cocci whereas the ΔCpsA strain with 
empty plasmid has frequencies ranging from two to four cocci per chain all the way to 
thirty to thirty-two cocci per chain (Compare Figure 7 to Figure 8).  
When a plasmid expressing the Wild Type cpsA is added to the Wild Type GBS 
strain, the chain length is slightly decreased even more compared to the Wild Type strain 
with empty plasmid (Figure 6, columns 1 and 2). With the ΔCpsA strain with empty 
plasmid showing a much greater average number of cocci per chain, the ΔCpsA strain 
with Wild Type cpsA plasmid complements the phenotype back to Wild Type strain with 
empty plasmid chain length levels (Figure 6, column 4). This indicates that adding the 
Wild Type cpsA plasmid allows for relatively normal morphology expression.  
The Wild Type strain with cpsA mutant plasmid shows the same number of cocci 
per chain as the Wild Type strain with Wild Type cpsA plasmid (Figure 6, columns 4 and 
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5). The ΔCpsA strain with cpsA mutant plasmid shows a similar average number of cocci 
per chain as the ΔCpsA strain with empty plasmid (Figure 6, compare column 3 and 4). 
While the ΔCpsA strain with cpsA mutant plasmid does not complement the phenotype 
completely back to ΔCpsA strain with empty plasmid levels, there is a significant 
increase from the ΔCpsA strain with Wild Type cpsA plasmid levels (Figure 6, columns 
3, 5, 6). This is further seen by the frequency of the number of cocci per chain in the Wild 
Type with cpsA Mutant Plasmid to be only between one and three (Figure 9). This is 
similar to the frequencies seen of the Wild Type with empty plasmid strain. The ΔCpsA 
with cpsA Mutant Plasmid still has a high frequency of short chain lengths ranging 
between one and three, but it also has a broader range of cocci per chain as well as higher 
frequency of longer chains with nine to eleven cocci (Figure 10).  
Figure 6 
 Figure 6. Number of Cocci per Chain Comparison. Six microliters of each strain type 
were placed on a slide and ten fields of view were imaged. The number of cocci per chain 
were counted. Error bars represent Standard Error of the Mean. Minimum N = 201. The 









Figure 7. Wild Type with Empty Plasmid Frequency of cocci per chain. The 
most frequent number of chain lengths was between one and three. 	
Figure 8. ΔCpsA with Empty Plasmid Frequency of cocci per chain. The most 
frequent number of cocci per chain length was between one and four, however there was 
also an increased number of chains with greater than ten cocci per chain, which is not 










Figure 9. ΔCpsA with cpsA Mutated Plasmid Frequency of number of cocci 
per chain counts. The chains most frequently had between one and three cocci 
with not chains having more than five cocci.	
Figure 10. ΔCpsA with cpsA Mutant Plasmid Frequency of number of 
cocci per chain. The highest frequency of cocci per chain was between one 
and four. This strain also had an increased number of chains with 





 In the ELISA, alkaline phosphatase units directly correlate with the amount of 
serotype 1a capsule on the GBS cell surface. The Wild Type strain with empty plasmid 
showed the highest amount of alkaline phosphatase (AP) units at 6910 (Figure 11). The 
lowest amount of alkaline phosphatase units was the ΔCpsA strain with empty plasmid, 
5407 AP units. The Wild Type strain with cpsA mutant plasmid showed a decrease in 
capsular expression when compared to the Wild Type strain with empty plasmid but 
increased when compared to the ΔCpsA strain with empty plasmid. The ΔCpsA strain 
with the mutant cpsA plasmid is seen to almost fully complement capsular levels back to 
that of the Wild Type strain with empty plasmid. The ΔCpsA strain with cpsA mutant 
plasmid shows a greater than 1,200 AP UNITS increase in capsule when compared to the 





When zebrafish are injected with a negative control (sterile media), there is close 
to 100% survival rate 72 hours post infection (Figure 12). When injected with the Wild 
Type strain with empty plasmid, there is almost 80% death 72 hours post infection. The 
fish injected with the ΔCpsA strain with empty plasmid are seen to have around 90% 
death. Zebrafish injected with the ΔCpsA with cpsA mutant plasmid are seen to have 
around 80% death at 72 hours post infection, similar to the percentage survival of the 
Wild Type strain with empty plasmid. The ΔCpsA strain with cpsA mutant plasmid also 
shows survival levels similar to the negative control infection at 24 hour post infection, 
but sharply drops to 50% at 48 hours post infection (Figure 12).  
Figure 12	
Figure 11. ELISA Polysaccharide Capsule Comparisons. Adjusted averages are 
shown. These are calculated through subtracting the background values of the 






Chain length, polysaccharide expression, and virulence were examined to assess 
the effect an amino acid change in the CpsA protein sequence. Through comparisons to 
the normal Wild Type strain with empty plasmid and ΔCpsA strain with empty plasmid, 
the specific changes that occur were analyzed. Analysis of the effects of mutational 
changes   may provide a greater degree of understanding of GBS as a pathogen and what 
specific residues play key roles in its virulence.  
Colony Morphology 
The Wild Type strain with cpsA mutant plasmid has similar chain lengths to the 
Wild Type strain with empty plasmid, this means that the mutation did not affet chain 
length in the Wild Type strain (Figure 6). In comparing the frequency of the number of 
Figure 12. Survival Curve in Zebrafish Comparison. Zebrafish were 
infected with either a negative control of THY-B, and Wild Type with Empty 
Plasmid, ΔCpsA with Empty Plasmid, or ΔCpsA strain with Mutant Plasmid. 
Fish were observed at 24, 48, and 72 hours post infection. Data are 
representative of two trials, each of 20 fish. 	
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cocci per chain, this remains consistent between the Wild Type strain with cpsA mutant 
plasmid and the Wild Type strain with empty plasmid (Figures 7 and 9). Therefore, there 
is not a dominant negative effect when adding the mutated form of cpsA into the Wild 
Type strain.  
However, when the mutant plasmid is added to the ΔCpsA strain, there is 
complementation back to similar levels of the ΔCpsA strain with empty plasmid (Figure 
6). This complementation can also be seen in the frequency of number of cocci per chain 
between both ΔCpsA strains (Figures 8 and 10). Although, the mutation to the one amino 
acid does not cause chain lengths to be as high as ΔCpsA strain with empty plasmid, it 
does indicate that the single mutation does have an effect.  
ELISA 
Capsule expression in the Wild Type strain with cpsA mutant plasmid shows a 
slight decrease when compared to the Wild Type strain with empty plasmid. This 
indicates that the mutated plasmid could have a dominant negative effect on the Wild 
Type strain when observing the amount of capsule on the cell. The ΔCpsA strain with 
mutant plasmid shows a much greater amount of capsule compared to the ΔCpsA with 
empty plasmid. This indicates that adding the mutated plasmid into the ΔCpsA strain 
brings back capsule expression back to a level that is more consistent with Wild Type 
strain values. When compared to the results of the number of cocci per chain, the 
variability shows that the single mutation causes an intermediate phenotypic expression. 
Zebrafish Infections 
Using the zebrafish model of infectious disease, zebrafish survival after infection 
was observed when comparing different strains of Group B Streptococcus 515. The 
results indicate the one mutation of arginine to alanine in the metal binding region of the 
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Lyt-R domain does not cause a significant decrease in virulence. Instead, a similar 
percentage of survival was observed for the ΔCpsA strain with the mutant cpsA plasmid 
as the wild type strain (Figure 12).  
 One hypothesized reason for these results is the type of mutation that was made 
may not have been different enough to cause a significant effect using the assays in this 
project. Arginine is a positively charged, aliphatic amino acid whereas alanine is a 
nonpolar, aliphatic amino acid. The magnesium metal binding triad consists of two 
negatively charged aspartic acids and one arginine. Previous research involved mutating 
the two aspartic acids to alanine indicated that this change caused an increase in number 
of cocci per chain as well as a decrease in polysaccharide capsule expression. The 
arginine in this metal binding pocket has been shown to coordinate the two aspartic acids 
that complete the triad11. Thus, the arginine amino acid does not directly interact with the 
magnesium molecule. This indirect relation could be the reason that the mutation to the 
arginine residue in this research does not have a profound impact on the binding ability of 
the metal ion. In Wild Type strains, only the two aspartic acids are directly affecting the 
placement of the magnesium ion while the arginine stabilizes the transition state. When 
mutated to alanine, there was variable results since there was no effect on the other two 
residues in the metal binding pocket. Because of this, the binding ability to the 
magnesium metal was not directly affected, only the coordination and stability of the 
arrangement. This issue in stability could explain why the results were variable.  
Future Directions 
 Subsequent trials are needed to replicate the results and ensure greater statistical 
significance. The ELISA should be performed again for further validation. The zebrafish 
injections should also be repeated as there is a possibility of contamination in the ΔCpsA 
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strain with the ΔcpsA mutant plasmid as well as mutations caused by the age of the adult 
zebrafish bred from. 
Further research to be completed would be combining the two aspartic acid 
mutations with the one arginine mutation, thus mutating all three of the amino acids in 
the magnesium metal binding region. This would aid in determining the direct and 
holistic effects the magnesium binding has on capsule production, ligation, and colony 
morphology. With the removal of the entire metal binding site, these results could show a 
higher degree of decreased capsule production. The two aspartic acids were not tested for 
virulence in the zebrafish model, this research should be conducted in the future. 
Additional zebrafish infection trials should be completed with various inoculums. In 
previous research, adult zebrafish were used compared to the two day old fish that were 
used in this study.   There is a possibility that the 100 CFU dose of bacteria was too much 
for the age of fish that were used and could have caused the results to not accurately 
depict the virulence of the bacteria. Subsequent trials should perform the infections using 
a lower dose of 10 CFUs instead. More infection trials should also be done so neutrophil 
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